-$0.24 Earnings Per Share Expected for Mesoblast limited (NASDAQ:MESO) This Quarter

Share on StockTwits

Equities research analysts forecast that Mesoblast limited (NASDAQ:MESO) will post ($0.24) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Mesoblast’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Mesoblast posted earnings per share of ($0.22) in the same quarter last year, which suggests a negative year over year growth rate of 9.1%. The company is expected to issue its next earnings results on Wednesday, September 4th.

According to Zacks, analysts expect that Mesoblast will report full-year earnings of ($0.93) per share for the current financial year, with EPS estimates ranging from ($1.00) to ($0.82). For the next year, analysts expect that the firm will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.08) to ($0.85). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Mesoblast.

Mesoblast (NASDAQ:MESO) last announced its quarterly earnings results on Thursday, May 30th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $1.23 million. Mesoblast had a negative return on equity of 17.13% and a negative net margin of 546.34%.

Several analysts have recently weighed in on the company. Maxim Group restated a “buy” rating and set a $16.00 target price on shares of Mesoblast in a research note on Wednesday, June 12th. Chardan Capital set a $6.00 target price on Mesoblast and gave the company a “hold” rating in a research note on Friday, May 31st. Zacks Investment Research upgraded Mesoblast from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. ValuEngine upgraded Mesoblast from a “hold” rating to a “buy” rating in a research note on Wednesday, June 26th. Finally, HC Wainwright assumed coverage on Mesoblast in a research note on Wednesday, June 5th. They set a “buy” rating and a $7.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $12.13.

Shares of Mesoblast stock remained flat at $$4.95 during trading hours on Wednesday. The stock had a trading volume of 10 shares, compared to its average volume of 30,263. The stock has a fifty day moving average of $5.09 and a 200 day moving average of $5.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.92 and a current ratio of 1.92. The stock has a market cap of $449.20 million, a P/E ratio of -7.86 and a beta of 1.84. Mesoblast has a 12 month low of $3.35 and a 12 month high of $8.78.

A hedge fund recently raised its stake in Mesoblast stock. Morgan Stanley boosted its position in Mesoblast limited (NASDAQ:MESO) by 284.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the period. Morgan Stanley owned about 0.16% of Mesoblast worth $784,000 as of its most recent SEC filing. 2.71% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

See Also: What is the Dow Jones Industrial Average (DJIA)?

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

OTCMKTS:PROSY  Now Covered by Analysts at Barclays
OTCMKTS:PROSY Now Covered by Analysts at Barclays
Exagen  Coverage Initiated by Analysts at Cowen
Exagen Coverage Initiated by Analysts at Cowen
Square  Receives New Coverage from Analysts at UBS Group
Square Receives New Coverage from Analysts at UBS Group
$248.92 Million in Sales Expected for ExlService Holdings, Inc.  This Quarter
$248.92 Million in Sales Expected for ExlService Holdings, Inc. This Quarter
XcelToken Plus  Tops 24-Hour Volume of $3,040.00
XcelToken Plus Tops 24-Hour Volume of $3,040.00
PDATA  Reaches 24-Hour Volume of $8,278.00
PDATA Reaches 24-Hour Volume of $8,278.00


© 2006-2019 Ticker Report